Elsevier

Journal of Nuclear Cardiology

Volume 29, Issue 6, December 2022, Pages 3057-3068
Journal of Nuclear Cardiology

Original Article
Anti-inflammatory effect of rosuvastatin in patients with HIV infection: An FDG-PET pilot study

https://doi.org/10.1007/s12350-021-02830-4Get rights and content

Abstract

Aims

This study aimed to evaluate markers of systemic as well as imaging markers of inflammation in the ascending aorta, bone marrow, and spleen measured by 18F-FDG PET/CT, in HIV+ patients at baseline and following therapy with rosuvastatin.

Methods and results

Of the 35 HIV+ patients enrolled, 17 were randomized to treatment with 10 mg/day rosuvastatin and 18 to usual care for 6 months. An HIV− control cohort was selected for baseline comparison of serum inflammatory markers and monocyte markers of inflammation. 18F-FDG-PET/CT imaging of bone marrow, spleen, and thoracic aorta was performed in the HIV+ cohort at baseline and 6 months. While CD14++CD16− and CCR2 expressions were reduced, serum levels of IL-7, IL-8, and MCP-1 were elevated in the HIV+ population compared to the controls. There was a significant drop in FDG uptake in the bone marrow (TBRmax), spleen (SUVmax) and thoracic aortic (TBRmax) in the statin-treated group compared to the control group (bone marrow: − 10.3 ± 16.9% versus 5.0 ± 18.9%, p = .0262; spleen: − 9.8 ± 20.3% versus 11.3 ± 28.8%, p = .0497; thoracic aorta: − 19.1 ± 24.2% versus 4.3 ± 15.4%, p = .003).

Conclusions

HIV+ patients had significantly markers of systemic inflammation including monocyte activation. Treatment with low-dose rosuvastatin in the HIV+ cohort significantly reduced bone marrow, spleen and thoracic aortic FDG uptake.

Introduction

Patients with human immunodeficiency virus (HIV) have a significantly increased risk of cardiovascular disease (CVD).1 HIV+ individuals are 2-4 times more likely to suffer a myocardial infarction (MI),2,3 and CVD now accounts for 10% of all deaths in this population.1 HIV infection is associated with accelerated progression of atherosclerosis, an association that appears to be independent of traditional CVD risk factors.4

Atherosclerosis is a multi-faceted disease with inflammation playing a central role in atherosclerosis initiation and progression, and the triggering of events such as MI and stroke. HIV infection has been associated with persistently increased systemic inflammation, immune activation and pro-coagulant changes despite effective antiretroviral therapy.5 These effects are thought to drive endothelial dysfunction, monocyte/macrophage activation, and accelerated atherosclerosis, as well as MI and post-MI fibrosis and reduced left ventricular function.6 Monocyte-derived macrophages are a principal mediator of inflammation in atherosclerotic plaques.7,8 Activation of monocyte-derived macrophages infiltrating atherosclerotic plaques appears to occur at early stages in the bone marrow and spleen.9,10

Statins are a widely prescribed lipid-lowering drug-class that reduces cardiovascular morbidity and mortality in both primary and secondary prevention.11 In addition to their lipid-lowering effects, statins may have additional pleiotropic effects, including improvements in endothelial function, stabilization of atherosclerotic plaques, anti-inflammatory, immune-modulatory and anti-thrombotic effects.12 Tissue uptake of 18F-fluorodeoxyglucose (18F-FDG) as measured by 18F-FDG positron emission tomography/computed tomography (PET/CT) scanning is a widely employed and sensitive technique for directly assessing inflammation in arterial walls and other organs such as the spleen and bone marrow. This is because inflammatory cells (mainly macrophages) have higher metabolic activity (i.e. higher rate of glycolysis) than other organ specific cell types (i.e. smooth muscle cells, endothelial cells, fibroblasts, osteoblasts, T-lymphocytes, etc.).13 Given the potential link between inflammation and accelerated atherosclerosis in HIV+ patients, in this study we use 18F-FDG PET/CT to quantify regional haemopoietic activity14 and inflammation as measured by FDG bone marrow, spleen and ascending aorta uptake in HIV+ patients with moderate CVD risk, and also measured markers of monocyte activation in this group. We hypothesized that monocyte markers of inflammation would be elevated in an HIV+ cohort compared to an HIV− cohort. Furthermore, in our HIV+ cohort, we hypothesized that imaging markers of inflammation in the ascending aorta as well as bone marrow and spleen as measured by 18F-FDG PET/CT, as well as markers of systemic inflammation including monocyte activation and markers of monocyte activation would improve in HIV+ patients with moderate CVD risk randomized to therapy with rosuvastatin compared to HIV+ patients randomized to standard of care.

Section snippets

Methods

Participants were enrolled from the Immunodeficiency Clinic at the Ottawa Hospital General Campus, Ottawa, Ontario, Canada. Eligible participants were those with documented serologic evidence of HIV infection; ≥ 40 years of age; receiving standard ART for >2 years with a viral load below the limits of detection while on ART, a current CD4 count >350 cells/μL; and with a baseline Framingham risk score of 10-20%. Nine HIV- controls with no known cardiovascular disease were selected as age matched

Baseline participant characteristics

Thirty-five HIV+ patients were recruited, 86% of whom were men. Average age was 51.5 ± 6.9 years and the average BMI was 25.7 ± 3.8 kg/m2. Participants were well-matched between the treatment groups, with regards to CVD risk factors, with the exception of BMI, which was higher in the patients receiving statin treatment as well as the proportion of male sex, which was higher in the control group. Additionally, groups were matched with regards to age, sex, smoking, Framingham risk, duration of

Discussion

The present pilot study demonstrated that, in a cohort of HIV+ patients with moderate cardiovascular risk and on optimal medical therapy, there were elevated levels of baseline inflammation as measured by monocyte expression, serum inflammatory markers and FDG-PET markers of inflammation in the bone marrow, spleen and ascending aorta. In addition, treatment with low-dose rosuvastatin for 6 months resulted in significantly decreased FDG uptake in the bone marrow, spleen and thoracic aorta in the

Conclusions

In conclusion, the present study observed that monocyte markers of inflammation were elevated in HIV+ patients compared to HIV- controls. Additionally, there was a significant decrease in FDG-PET uptake in the bone marrow, spleen, and thoracic aorta following treatment with rosuvastatin for 6 months in HIV+ patients compared to HIV+ patients receiving usual care. These data suggest wide-range anti-inflammatory effects of rosuvastatin in HIV+ individuals with well-controlled infection on ART,

Acknowledgments

This study was supported by Ontario HIV Treatment Network (OHTN) grant support ($374252). KEB is supported by a CIHR Fellowship Award. RSBB was a Career Investigator supported but the Heart and Stroke Foundation of Ontario, the UOHI Vered Chair of Cardiology and a University of Ottawa Distinguished Chair of Cardiovascular Imaging Research. PM is supported by a Research Chair from the OHTN. GD was supported by a CIHR new investigator salary support award (supported by OHTN) while at UOHI.

Disclosures

EF, JW,

References (61)

  • BlumA et al.

    The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis

    Atherosclerosis

    (2009)
  • LoJ et al.

    Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: A randomised, double-blind, placebo-controlled trial

    Lancet HIV.

    (2015)
  • HsuePY et al.

    IL-1beta inhibition reduces atherosclerotic inflammation in HIV infection

    J Am Coll Cardiol

    (2018)
  • ThakoreAH et al.

    Association of multiple inflammatory markers with carotid intimal medial thickness and stenosis (from the Framingham Heart Study)

    Am J Cardiol

    (2007)
  • YudkinJS et al.

    Inflammation, obesity, stress and coronary heart disease: Is interleukin-6 the link?

    Atherosclerosis

    (2000)
  • AryaAK et al.

    Correlation between IL-7 and MCP-1 in diabetic chronic non healing ulcer patients at higher risk of coronary artery disease

    Cytokine

    (2012)
  • FryTJ et al.

    A potential role for interleukin-7 in T-cell homeostasis

    Blood

    (2001)
  • Antiretroviral Therapy Cohort C. Causes of death in HIV-1-infected patients treated with antiretroviral therapy,...
  • BoccaraF

    Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: Type, incidence and associated risk factors

    AIDS

    (2008)
  • TriantVA et al.

    Association of C-reactive protein and HIV infection with acute myocardial infarction

    J Acquir Immune Defic Syndr

    (2009)
  • FreibergMS et al.

    HIV infection and the risk of acute myocardial infarction

    JAMA Intern Med

    (2013)
  • HsuePY et al.

    Inflammation and fibrosis in HIV: Getting to the heart of the matter

    Circ Cardiovasc Imaging

    (2016)
  • JonassonL et al.

    Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque

    Arteriosclerosis

    (1986)
  • van der Wal AC, Das PK, Bentz van de Berg D, van der Loos CM and Becker AE. Atherosclerotic lesions in humans. In situ...
  • RobbinsCS et al.

    Extramedullary hematopoiesis generates Ly-6C(high) monocytes that infiltrate atherosclerotic lesions

    Circulation

    (2012)
  • MurphyAJ et al.

    ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice

    J Clin Invest

    (2011)
  • Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R and...
  • Cocker MS, Spence JD, Hammond R, deKemp RA, Lum C, Wells G, Bernick J, Hill A, Nagpal S, Stotts G, Alturkustani M,...
  • IslamFM et al.

    Relative risk of cardiovascular disease among people living with HIV: A systematic review and meta-analysis

    HIV Med

    (2012)
  • MarcusJL et al.

    HIV infection and incidence of ischemic stroke

    AIDS

    (2014)
  • Cited by (0)

    Paul MacPherson and Girish Dwivedi are co-senior author.

    View full text